Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Thursday. The firm issued a hold rating on the stock.

A number of other research analysts have also recently commented on the stock. HC Wainwright reiterated a buy rating and set a $10.00 price target on shares of Ekso Bionics in a research report on Tuesday, July 30th. Lake Street Capital started coverage on shares of Ekso Bionics in a research note on Monday, June 24th. They issued a buy rating and a $2.50 price target for the company.

Ekso Bionics Stock Up 3.9 %

Shares of NASDAQ EKSO opened at $1.06 on Thursday. The company has a current ratio of 2.42, a quick ratio of 1.77 and a debt-to-equity ratio of 0.36. Ekso Bionics has a 12 month low of $0.74 and a 12 month high of $3.13. The firm has a market capitalization of $19.26 million, a price-to-earnings ratio of -1.09 and a beta of 1.45. The business has a 50-day moving average of $1.09 and a 200-day moving average of $1.18.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The company had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. During the same quarter last year, the firm posted ($0.31) earnings per share. Sell-side analysts expect that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is owned by institutional investors and hedge funds.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.